EUVIMEDEUVIMED entdecken
Crossref

MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy

Lan Zhang, Quan-Xiang Cui, Liang-Qin Zhou, Xin-Yi Wang, Hong-Xia Zhang, Yue-Min Zhu, Xi-Qiao Sang, Zi-Xiang Kuai

Computerized Medical Imaging and Graphics · 2024

DOI: 10.1016/j.compmedimag.2024.102443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Computerized Medical Imaging and Graphics, 2024. Verfasst von Lan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No. 150, Nangang District, Harbin, 150081, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Magnetic Resonance Imaging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To develop a novel MRI-based vector radiomic approach to predict breast cancer (BC) human epidermal growth factor receptor 2 (HER2) status (zero, low, and positive; task 1) and its changes after neoadjuvant therapy (NAT) (positive-to-positive, positive-to-negative, and positive-to-pathologic complete response; task 2). MATERIALS AND METHODS: Both dynamic contrast-enhanced (DCE) MRI data and multi-b-value (MBV) diffusion-weighted imaging (DWI) data were acquired in BC patients at two centers. Vector-radiomic and conventional-radiomic features were extracted from both DCE-MRI and MBV-DWI. After feature selection, the following models were built using the retained features and logistic regression: vector model, conventional model, and combined model that integrates the vector-radiomic and conventional-radiomic features. The models' performances were quantified by the area under the receiver-operating characteristic curve (AUC). RESULTS: The training/external test set (center 1/2) included 483/361 women. For task 1, the vector model (AUCs=0.73∼0.86) was superior to (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesMagnetic Resonance ImagingHumansFemaleMiddle AgedAdultAgedPredictive Value of TestsDiffusion Magnetic Resonance ImagingContrast MediaRadiomics

Stichwörter der Autor:innen

Breast cancerHER2Magnetic resonance imagingNeoadjuvant therapyRadiomics

Substanzen

Erb-b2 Receptor Tyrosine KinasesContrast MediaERBB2 protein, human

Autor:innen und Institutionen

  • Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No. 150, Nangang District, Harbin, 150081, China.
  • CREATIS, CNRS UMR 5220-INSERM U1206-University Lyon 1-INSA Lyon-University Jean Monnet Saint-Etienne, Lyon 69621, France.
  • Division of Respiratory Disease, Fourth Affiliated Hospital of Harbin Medical University, Yiyuan Street No. 37, Nangang District, Harbin, 150001, China.
  • Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No. 150, Nangang District, Harbin, 150081, China. Electronic address: zixiangkuai@126.com.

Zitieren

APA

Zhang, L., Cui, Q. X., Zhou, L. Q., Wang, X. Y., Zhang, H. X., Zhu, Y. M., Sang, X. Q., & Kuai, Z. X. (2024). MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy. Computerized Medical Imaging and Graphics. https://doi.org/10.1016/j.compmedimag.2024.102443

Vancouver

Zhang L, Cui QX, Zhou LQ, Wang XY, Zhang HX, Zhu YM, et al. MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy. Computerized Medical Imaging and Graphics. 2024. doi:10.1016/j.compmedimag.2024.102443

BibTeX
@article{Zhang2024,
  author = {Zhang, Lan and Cui, Quan-Xiang and Zhou, Liang-Qin and Wang, Xin-Yi and Zhang, Hong-Xia and Zhu, Yue-Min and Sang, Xi-Qiao and Kuai, Zi-Xiang},
  title = {MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy},
  journal = {Computerized Medical Imaging and Graphics},
  year = {2024},
  doi = {10.1016/j.compmedimag.2024.102443}
}
Kostenlos starten →